-
Aclarion publishes Nociscan article in spine surgery journal
-
Aclarion names Jason Brosniak commercial director for eastern U.S.
-
Aclarion hires Dan Isherwood as UK commercial director
-
Aclarion reports 89% surge in scan volumes, advances trial
-
Aclarion presents MR spectroscopy pain biomarker tech at London conference
-
Aclarion to Present at the LD Micro Main Event XIX
-
Aclarion reports 132% growth in Nociscan scan volume
-
Aclarion (ACON) postpones annual shareholder meeting to July 21
-
Aclarion (ACON) Provides Update on Strength of Company Positioning Following Q1 Strategic Initiatives
-
Aclarion (ACON) Announces 1:27 Reverse Share Split
-
Aclarion (ACON) Announces Expansion Plans with RadNet Affiliates in NY and NJ
-
Aclarion (ACON) Announces First Commercial Agreement with Scripps Health
-
Aclarion (ACON) Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy Data Processing
-
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
-
Aclarion's (ACON) Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
-
Aclarion (ACON) Provides Corporate Update on Nociscan AI Technology Milestones

